Skip to main content

Search Videos and More

Showing 85 - 96 of 162 results

Previous| 1... 7 | 8 | 9 ...14 |Next

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?

Assuming optimization of patient outcomes, rather than cost, is the primary driver governing use of PCSK9 inhibitors, which patients in a medical cardiology practice would you single out for this therapy, and to achieve what LDL-C target levels?

Assuming optimization of patient outcomes, rather than cost, is the primary driver governing use of PCSK9 inhibitors, which patients in a medical cardiology practice would you single out for this therapy, and to achieve what LDL-C target levels?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

What unique aspects, with respect to all-cause mortality outcomes and baseline LDL-C levels, were observed in the ODYSSEY Outcomes Trial and how would you translate these results into patient care?

What unique aspects, with respect to all-cause mortality outcomes and baseline LDL-C levels, were observed in the ODYSSEY Outcomes Trial and how would you translate these results into patient care?

How do you recommend managing the patient who has a major CV/thrombotic event—a recent MI—who is on a statin and has an LDL-C level of 60-70 mg/dL? How does the ODYSSEY Outcome Trial and/or IVUS studies help you assess the role of a PCSK9 inhibitor?

How do you recommend managing the patient who has a major CV/thrombotic event—a recent MI—who is on a statin and has an LDL-C level of 60-70 mg/dL? How does the ODYSSEY Outcome Trial and/or IVUS studies help you assess the role of a PCSK9 inhibitor?

What would your approach be to a 57-year-old man with an LDL-C of 70 mg/dL who has recently had an ACS event and now develops recurrent ACS, or a new stent thrombosis? Does ODYSSEY Outcomes provide any evidence-based guidance?

What would your approach be to a 57-year-old man with an LDL-C of 70 mg/dL who has recently had an ACS event and now develops recurrent ACS, or a new stent thrombosis? Does ODYSSEY Outcomes provide any evidence-based guidance?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

Now, with the publication of ODYSSEY Outcomes, which demonstrated an associated, all-cause mortality reduction benefit, how do you view the foundational role of PCSK9 inhibitors in the CV risk treatment plan for high-risk patient populations?

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors?

From a lipid medicine and atherosclerosis expert’s perspective, when you look at the ODYSSEY Outcomes and Fourier Trials, what consistent or comparative message do you take from these investigations into the safety and efficacy of PCSK9 inhibitors?

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER?

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER?

Showing 85 - 96 of 162 results

Previous| 1... 7 | 8 | 9 ...14 |Next